Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

You Lu

Showing results (541-550 of 547) with videos related to

Pageof 55
Sort By:
You have reached the last page of results.This site can display upto 547 results.
Nature Cancer|April 22, 2022
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogrammingFeifei Na, Xiangyu Pan, Jingyao Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
Cancer Biology & Medicine|May 24, 2019
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologyXuchao Zhang, Zhiyong Liang, Shengyue Wang, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.
ESMO Open|August 30, 2017
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Yan Sun, et al.
Pageof 55

Showing results (541-550 of 547) with videos related to

Sort By:
Pageof 55
You have reached the last page of results.This site can display upto 547 results.
Nature Cancer|April 22, 2022
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogrammingFeifei Na, Xiangyu Pan, Jingyao Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
Cancer Biology & Medicine|May 24, 2019
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologyXuchao Zhang, Zhiyong Liang, Shengyue Wang, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
The New England Journal of Medicine|July 8, 2026
Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung CancerDongsheng Yue, Meijuan Huang, Pingping Song, et al.
ESMO Open|August 30, 2017
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panelYi-Long Wu, Chang-Li Wang, Yan Sun, et al.
Pageof 55